Morgan Stanley
DFTX

Morgan Stanley’s Definium Therapeutics DFTX Stock Holding History

Morgan Stanley’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.4M Buy
454,912
+16,339
+4% +$404K ﹤0.01% 3033
2026
Q1 		$8.29M Buy
438,573
+71,878
+20% +$1.22M ﹤0.01% 3726
2025
Q4 		$4.91M Sell
366,695
-128,923
-26% -$1.6M ﹤0.01% 4185
2025
Q3 		$5.84M Sell
495,618
-192,913
-28% -$1.8M ﹤0.01% 4020
2025
Q2 		$4.47M Buy
688,531
+28,639
+4% +$188K ﹤0.01% 4140
2025
Q1 		$3.86M Buy
659,892
+163,240
+33% +$1.17M ﹤0.01% 4146
2024
Q4 		$3.46M Buy
496,652
+141,033
+40% +$970K ﹤0.01% 4296
2024
Q3 		$2.02M Buy
355,619
+197,638
+125% +$1.37M ﹤0.01% 4639
2024
Q2 		$1.14M Buy
157,981
+47,019
+42% +$411K ﹤0.01% 4882
2024
Q1 		$1.04M Buy
110,962
+88,101
+385% +$502K ﹤0.01% 4932
2023
Q4 		$83.7K Sell
22,861
-12,741
-36% -$38.4K ﹤0.01% 6012
2023
Q3 		$111K Buy
35,602
+5,569
+19% +$22.9K ﹤0.01% 5848
2023
Q2 		$107K Sell
30,033
-7,008
-19% -$24.2K ﹤0.01% 5922
2023
Q1 		$117K Sell
37,041
-15,914
-30% -$52.9K ﹤0.01% 5945
2022
Q4 		$117K Buy
52,955
+26,583
+101% +$73.8K ﹤0.01% 5912
2022
Q3 		$92K Sell
26,372
-22,221
-46% -$213K ﹤0.01% 6120
2022
Q2 		$468K Sell
48,593
-83,027
-63% -$1.05M ﹤0.01% 5457
2022
Q1 		$2.19M Sell
131,620
-28,372
-18% -$492K ﹤0.01% 4458
2021
Q4 		$3.31M Buy
159,992
+147,003
+1,132% +$4.69M ﹤0.01% 4157
2021
Q3 		$453K Buy
12,989
+1,527
+13% +$66K ﹤0.01% 5560
2021
Q2 		$594K Buy
+11,462
New +$602K ﹤0.01% 5416

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Morgan Stanley's DFTX Position: Q2 2026 in Review

Morgan Stanley increased its Definium Therapeutics (DFTX) stake by 3.7% in Q2 2026, buying an estimated $404K and bringing the position to 454,912 shares worth $21.4M. The position accounts for ﹤0.01% of the portfolio, ranked #3033.

Morgan Stanley first reported a position in DFTX in Q2 2021 and has held it in 21 quarters since. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • Morgan Stanley held 454,912 shares of Definium Therapeutics worth $21.4M as of Q2 2026.
  • Morgan Stanley bought 16,339 Definium Therapeutics shares in Q2 2026, an estimated $404K.
  • Definium Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #3033 holding.
  • Morgan Stanley first reported a position in Definium Therapeutics in Q2 2021 and has held it in 21 quarters since.
  • 362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.